Although the market is expected to experience strong growth, the quality of care is inconsistent.
Economic development in China has created a burgeoning middle class that demands higher standards of living.
The President’s actions (or distractions) may be detrimental to Western medical device companies.
As standalone software becomes increasingly sophisticated, a number of regulatory bodies have begun to draft separate guidelines to ensure quality control, expedite product approval, and improve patient access to new technologies.
Global sports medicine is predicted to grow to around $35 billion by 2022, with the Asian market growing at a compound annual growth rate of nearly 7 percent.
Increased prevalence and awareness of neurological disorders in Asia present market growth opportunities for neurology companies.
Growth of the Asian cloud computing market is expected to accelerate as healthcare providers streamline their operations in today’s paperless world.
Cost savings and the ability to meet high-volume demands are enticing benefits.
Low-cost production centers make these markets an attractive option for manufacturing.
China’s medtech influence is beginning to threaten the West’s dominance.